Urology news for Sunday, November 15, 2026
Top 5 in urology
- FDA approves durvalumab with enfortumab vedotin for muscle-invasive bladder cancer FDA approval · FDA · 2026-11-13
FDA approved the perioperative combination of durvalumab (an immune checkpoint inhibitor) and enfortumab vedotin-ejfv for muscle-invasive bladder cancer.
Why it matters: Adds a new FDA-approved perioperative regimen option for muscle-invasive bladder cancer.
More Bladder cancer news - CHMP recommends EU approval of belzutifan plus lenvatinib for advanced ccRCC Intl regulatory · Urology Times · 2026-11-13
The European Medicines Agency's CHMP has issued a positive opinion recommending approval of belzutifan combined with lenvatinib for advanced clear cell renal cell carcinoma.
Why it matters: If ratified by the European Commission, this would add a new combination option for advanced ccRCC in Europe.
More Kidney cancer news - Claims data: psychiatric diagnoses common after cystectomy regardless of diversion type Retrospective · Urology · 2026-11-15
In a TriNetX claims analysis of over 13,000 cystectomy patients, neobladder recipients had a transient excess of new mood disorder diagnoses in the first month (RR 1.81) that equalized with ileal conduit patients by 6 months; roughly a quarter of all patients had a new or recurrent psychiatric diagnosis by 5 years.
Why it matters: Hypothesis generating from claims data lacking clinical detail; suggests mental health needs after cystectomy are common and not clearly tied to diversion type long-term.
More Bladder cancer news - Longer oral mucosa grafts for urethroplasty linked to more donor-site morbidity Retrospective · World J Urol · 2026-11-15
Among 304 patients who underwent oral mucosa graft urethroplasty (115 with strictures ≤5 cm, 189 with strictures >5 cm), 21.1% reported at least one significant oral complication on follow-up questionnaires (up to 12 years). Oral numbness occurred in 17.1% overall, more often in the longer-stricture group (20.1% vs 12.2%), and discomfort while smiling or laughing was significantly more frequent in that group (7.4% vs 0.9%, p=0.01), with trends toward more pain, trismus, and eating difficulty that did not all reach statistical significance.
Why it matters: These findings support surgical planning that minimizes graft length and favors buccal-only harvest sites when feasible to limit long-term donor-site symptoms.
More Reconstruction and trauma news - Propensity-matched study inconclusive on histologic subtype risk in bladder-preserved NMIBC Retrospective · Clin Genitourin Cancer · 2026-11-15
In a propensity score-matched cohort of 456 NMIBC patients, those with histologic subtypes, divergent differentiation or neuroendocrine components had imprecise progression (HR 1.30, 95% CI 0.36-4.66) and recurrence (HR 0.59, 95% CI 0.27-1.31) estimates versus conventional urothelial carcinoma.
Why it matters: Raises the question of bladder-preserving approaches in variant histology NMIBC but the small event count and wide confidence intervals prevent any practice conclusion.
More Bladder cancer news
Prostate cancer news
- Systematic review underlying new ACS guideline summarizes benefits and harms of PSA screening Meta-analysis · Cancer · 2026-11-13
A systematic review of 29 publications, including 23 from six randomized trials (PLCO, CAP, ERSPC, Goteborg-1, Rotterdam Pilot 1, ProScreen) and four observational studies, found PSA screening was associated with reduced incidence of advanced/metastatic disease and, in some trials, reduced prostate cancer-specific mortality, though findings on mortality were inconsistent.
Why it matters: Provides the evidence base, drawn from a systematic review of RCTs and observational studies, behind the updated ACS PSA screening guideline, useful for shared decision-making conversations.
- Meta-analysis: active surveillance shows similar mortality to surgery, but watchful waiting worse Meta-analysis · Clin Genitourin Cancer · 2026-11-13
Across 12 studies (36,993 patients), active surveillance showed no significant difference in cancer-specific or all-cause mortality versus radical prostatectomy, though evidence was underpowered; watchful waiting was associated with significantly higher cancer-specific and all-cause mortality than surgery.
Why it matters: Suggests active surveillance and watchful waiting are not interchangeable, though the active surveillance comparison remains underpowered.
- PSMA total tumor volume outpredicts SUV and PSA for overall survival in large PET registry Retrospective · J Nucl Med · 2026-11-13
Among 13,893 prostate cancer patients in the PROMISE PET Registry split into development (n=9271) and validation (n=4622) cohorts, PSMA total tumor volume predicted overall survival in the validation cohort with a C-index of 0.78 (95% CI, 0.77-0.80), outperforming whole-body SUVmean (0.62; 95% CI, 0.61-0.64) and PSA at PET (0.71; 95% CI, 0.69-0.72), and performing similarly to PSMA total lesion uptake (0.78) and PSA times TTV (0.77).
Why it matters: A straightforward volumetric PSMA PET measurement may offer a more reliable way to stratify overall survival risk than SUV or PSA alone.
- FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA PET agent FDA action · OncLive · 2026-11-12
FDA granted Breakthrough Therapy Designation to 64Cu-SAR-bisPSMA, a PSMA PET imaging agent, for detecting biochemically recurrent prostate cancer.
Why it matters: Designation may accelerate review of a new long-lived PSMA PET tracer option for recurrence imaging.
- NCCN adds ArteraAI post-prostatectomy test to guideline for biochemical recurrence risk News · Targeted Oncology · 2026-11-12
NCCN guidelines now include the ArteraAI test, an AI-based prognostic tool, for risk assessment after radical prostatectomy in the setting of biochemical recurrence.
Why it matters: Signals growing guideline incorporation of AI-based prognostic biomarkers into routine post-prostatectomy decision-making.
- ctDNA positivity before SBRT predicts rapid progression in oligoprogressive CRPC Retrospective · JAMA Netw Open · 2026-11-12
In this prespecified secondary analysis of the phase 2 TRAP trial, 19 of 77 evaluable patients (24.7%) were ctDNA-positive before SBRT; their 6-month progression-free survival was 21.1% versus 58.3% for ctDNA-negative patients, with median PFS of 3.0 versus 7.8 months (P = .003). Median overall survival was 27.2 months for ctDNA-positive patients and 33.6 months for ctDNA-negative patients.
Why it matters: Baseline ctDNA status may help identify oligoprogressive CRPC patients less likely to benefit from SBRT, supporting its potential use in selecting candidates for metastasis-directed therapy versus earlier systemic change.
- CT adds little over pelvic MRI for nodal staging in higher-risk prostate cancer, both poor vs pathology Retrospective · World J Urol · 2026-11-12
In 323 patients with unfavorable intermediate- or high-risk prostate cancer, MRI and CT showed only moderate agreement for nodal staging and both had low sensitivity (≤20%) versus surgical pathology; PSMA PET/CT performed better (AUC 0.86) in a subgroup with molecular imaging.
Why it matters: Raises the question of whether conventional CT adds meaningful nodal staging value when PSMA PET is available.
- PSMA-guided salvage surgery shows PSA decline but limited durable cancer control Study · Renal & Urology News · 2026-11-10
A study of PSMA PET-guided salvage lymph node dissection or metastasectomy reported PSA declines in many patients but limited long-term disease control.
Why it matters: Suggests PSMA-guided salvage surgery may offer short-term biochemical benefit without durable oncologic control in recurrent prostate cancer.
- Registered trial: phase 3 trial to test perioperative relugolix around radical prostatectomy Trial registered · ClinicalTrials.gov · 2026-11-10
A phase 3 trial will randomize about 268 men with high-risk localized or locally advanced prostate cancer to relugolix before and after radical prostatectomy versus surgery alone followed by relugolix, evaluating this LHRH antagonist in a perioperative role. Registered on ClinicalTrials.gov and not yet recruiting; estimated start 2027-01-31; planned enrollment 268.
- NICE recommends five AI tools for prostate cancer detection in England Intl regulatory · UKAuthority · 2026-11-10
NICE issued recommendations backing five AI-based software tools to assist detection of prostate cancer, intended for use within the English NHS.
Why it matters: Signals a regulatory pathway for AI-assisted prostate cancer detection that US-based urologists should track.
Bladder cancer news
- FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection FDA action · Urology Times · 2026-11-10
The FDA granted De Novo authorization to the Virtuoso Robotic System, a device intended for robotic resection of bladder tumors.
Why it matters: A new dedicated robotic platform for transurethral bladder tumor resection adds to options for NMIBC management.
- Reconstructed-data analysis: newer BCG-unresponsive NMIBC drugs do not outperform gem/doce Retrospective · Urol Oncol · 2026-11-11
Using reconstructed individual patient data from registration trials, researchers found that none of the FDA-approved BCG-unresponsive NMIBC therapies (nadofaragene, pembrolizumab, nogapendekin alfa inbakicept, TAR-200) showed higher 3-month complete response, durability of response, or disease-free survival than intravesical gemcitabine/docetaxel; gem/doce had higher papillary-cohort DFS than pembrolizumab…
Why it matters: Raises the question of whether gem/doce should remain the benchmark for newer approved agents, though cross-trial, reconstructed-data comparisons limit certainty.
- ANKTIVA plus BCG meets primary endpoint in randomized BCG-naive NMIBC trial RCT · Business Wire · 2026-11-09
The randomized QUILT-2.005 trial of ANKTIVA (nogapendekin alfa inbakicept) added to BCG met its primary endpoint in patients with BCG-naive non-muscle invasive bladder cancer, according to a company announcement; detailed results were not reported.
Why it matters: A positive randomized readout in the BCG-naive setting could expand use of this combination beyond the BCG-unresponsive population already approved.
- Israel approves ANKTIVA plus BCG for BCG-unresponsive NMIBC with CIS Intl regulatory · Business Wire · 2026-11-09
Israel's Ministry of Health approved ANKTIVA (nogapendekin alfa inbakicept) combined with BCG for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.
Why it matters: Adds another regulatory jurisdiction to the approval already in place in the US for this combination.
- Post hoc THOR analysis links durable tumor response to erdafitinib with longer survival Retrospective · BJU Int · 2026-11-10
A post hoc analysis of the THOR trial found that among erdafitinib-treated patients with FGFR-altered metastatic urothelial carcinoma, those with durable objective response had substantially longer 6-month landmark overall survival than those with non-durable response (HR 8.71).
Why it matters: Suggests response durability, not just objective response rate, may better capture clinical benefit with erdafitinib, though this is a non-prespecified secondary analysis.
Kidney cancer news
- Robotic IVC thrombectomy linked to less blood loss and fewer complications than open surgery Retrospective · BJU Int · 2026-11-14
In a single-center retrospective cohort of 226 patients with renal tumor IVC thrombi (Mayo I-IV), robot-assisted thrombectomy was associated with less blood loss, shorter stay, fewer transfusions and complications than open surgery, with similar survival after adjustment and propensity matching.
Why it matters: Suggests robotic IVC thrombectomy may offer perioperative advantages over open surgery at experienced centers, without apparent oncologic tradeoff, though data are retrospective and single-center.
- Liver transplant team involvement tied to fewer complications in high-level IVC thrombectomy Retrospective · Urol Oncol · 2026-11-14
In a 36-patient single-center cohort of level III/IV renal tumor thrombectomy, cases with liver transplant team involvement had fewer major complications (11% vs 50%) and less hepatic dysfunction (0% vs 39%), but associations were attenuated and lost significance after adjusting for year of surgery.
Why it matters: Hypothesis generating only; in this small single center series the signal weakened after adjusting for year of surgery, so a causal benefit is unproven.
Upper tract urothelial carcinoma news
- Lynch syndrome carriers show 4.4% urothelial cancer rate, mostly upper tract Retrospective · JCO Precis Oncol · 2026-11-14
In a registry of 3,274 genetically confirmed Lynch syndrome carriers, 144 (4.4%) developed 224 urothelial carcinomas, over half in the upper urinary tract; MSH2/EPCAM variant carriers had higher risk (HR 4.43) than those with other MMR gene variants.
Why it matters: Raises the question of whether MSH2/EPCAM carriers warrant closer urothelial surveillance than other Lynch syndrome genotypes, pending prospective validation.
- Delphi consensus of 73 UTUC experts agrees on 32 of 40 statements for non-metastatic UTUC care Guideline · Nat Rev Urol · 2026-11-13
A two-round, web-based Delphi survey of 73 international UTUC experts (urologists and medical oncologists) rated 40 statements on diagnosis, staging, and treatment of non-metastatic upper tract urothelial carcinoma. Consensus was reached on 32 of 40 statements (80%) across both rounds, offering expert-informed guidance given limited high-level evidence in this disease.
Why it matters: Offers pragmatic expert consensus to help reduce practice variability in non-metastatic UTUC, an area with limited randomized trial evidence, though it is not a formal clinical guideline.
- Single-port robotic nephroureterectomy via lower anterior access feasible in multicenter series Retrospective · Eur Urol · 2026-11-07
In 47 patients across five centers, single-port retroperitoneal nephroureterectomy with bladder cuff excision via a single extraperitoneal incision achieved 76.7% pentafecta at 12 months, with 6% grade 3+ complications and 15% recurrence at median 12.3-month follow-up.
Why it matters: Describes an emerging single-port surgical technique for UTUC; comparative data against standard approaches are still needed.
- Commentary: pathogenic germline variants in urinary tract cancers are common but often missed Review · Renal & Urology News · 2026-11-04
A commentary piece discusses evidence that pathogenic germline variants are prevalent among patients with urinary tract cancers yet frequently go undetected on standard testing pathways.
Why it matters: Underscores the gap in germline testing uptake in urothelial cancers, consistent with prior reports of low testing rates in UTUC.
- Germline testing performed in under 5% of UTUC patients in claims analysis Retrospective · JCO Oncol Pract · 2026-10-31
A nationwide claims-based analysis of 4,783 patients with newly diagnosed UTUC found only 4.5% underwent germline testing, with no increase from 2015-2023, including just 5.6% of those diagnosed before age 50 who meet guideline criteria.
Why it matters: Raises the question of whether UTUC care pathways are failing to integrate germline evaluation despite guideline endorsement for Lynch syndrome screening; claims data cannot capture reasons testing was not ordered.
- Meta-analysis links neoadjuvant chemotherapy to better survival before nephroureterectomy in UTUC Meta-analysis · Eur Urol Oncol · 2026-10-27
Pooling 30 studies (2384 patients, mostly retrospective) on neoadjuvant chemotherapy for upper tract urothelial carcinoma, pathologic complete response occurred in 11% and downstaging in 20%; neoadjuvant chemotherapy was associated with HR 0.56 for overall survival and 0.47 for cancer-specific survival versus upfront surgery.
Why it matters: Adds support for a neoadjuvant chemotherapy approach in UTUC, though most included data are retrospective and immunotherapy evidence remains limited.
- UroVysion shows modest sensitivity but high PPV for UTUC in cytology-negative patients Retrospective · World J Urol · 2026-10-20
In a retrospective study of 1,256 patients with upper tract lesions and negative urinary cytology, UroVysion FISH had 66.9% sensitivity, 82.7% specificity, and 94.0% PPV for UTUC, and was associated with high-grade disease, lymphovascular invasion, and muscle invasion.
Why it matters: Raises the question of UroVysion as an adjunct when cytology is negative, though its low NPV limits its use for ruling out UTUC.
- TROP-2 expression stays high in UTUC regardless of prior chemotherapy, unlike NECTIN-4 Retrospective · Eur Urol Open Sci · 2026-10-18
In 141 resected UTUC specimens, NECTIN-4 positivity was much lower after prior chemotherapy (9.3% vs 47% treatment-naive), while TROP-2 positivity remained near universal in both groups (97% vs 100%).
Why it matters: Suggests TROP-2 may be a more reliable ADC target than NECTIN-4 in UTUC patients previously treated with chemotherapy.
Testicular cancer news
- Testicular cancer incidence concentrated in high-HDI nations, mortality gap widening Study · Urology · 2026-10-28
GLOBOCAN-based analysis of 185 countries found 72,040 new testicular cancer cases and 9,068 deaths in 2022; incidence correlates with national development level while mortality-to-incidence ratio is far higher in lower-HDI regions, with cases projected to rise 22.7% and deaths 40% by 2050.
Why it matters: Highlights persistent global disparities in testicular cancer outcomes tied to treatment access rather than disease biology.
Adrenal tumors news
- Review questions need for universal biochemical workup of adrenal incidentalomas Review · Eur Urol Focus · 2026-11-01
This review argues that routine biochemical testing for pheochromocytoma may be omitted in homogeneous adrenal masses with 10 Hounsfield units or less on unenhanced CT, per 2023 European Society of Endocrinology guidance, while testing for mild autonomous cortisol secretion remains broadly recommended.
Why it matters: Offers a risk-stratified framework for adrenal incidentaloma workup that may reduce unnecessary biochemical testing in low-risk imaging phenotypes.
Penile and urethral cancer news
- Phase 2 trial registered: TROP-2 ADC plus PD-1 inhibitor for advanced penile cancer Trial registered · ClinicalTrials.gov · 2026-10-30
A newly registered single-arm phase 2 trial (SCOPE) plans to evaluate sacituzumab tirumotecan plus toripalimab as chemo-free second-line therapy in platinum-refractory advanced penile squamous cell carcinoma, a setting where current options shrink tumors in only 10-15% of cases. Registered on ClinicalTrials.gov and not yet recruiting; estimated start 2027-01-01; planned enrollment 31; single site.
Why it matters: Penile cancer has few second-line options; this trial addresses an unmet need with a TROP-2 targeted ADC combination.
Endourology and stone disease news
- Stone-related ED visits before surgery vary by modality, race, and neighborhood vulnerability Retrospective · Urology · 2026-11-09
In an analysis of over 1 million patients from an EHR network, acute stone-related healthcare utilization in the year before definitive surgery was higher before PCNL and lower before SWL versus ureteroscopy, and increased with Black race and higher social vulnerability index, but not rurality.
Why it matters: Raises the question of whether access barriers contribute to acute presentations before definitive stone surgery, warranting prospective evaluation.
BPH and male LUTS news
- Phase 2 trial registered testing paclitaxel prostate implant for BPH-related LUTS Trial registered · ClinicalTrials.gov · 2026-11-10
A randomized, double-blind, placebo-controlled phase 2 trial will evaluate RT-310, a paclitaxel prostate implant, for lower urinary tract symptoms due to BPH in about 86 patients. Registered on ClinicalTrials.gov and not yet recruiting; estimated start 2027-01; planned enrollment 86.
- New consensus statements issued on minimally invasive BPH surgical treatments Guideline · UroToday · 2026-11-09
A consensus panel issued statements on the role and application of minimally invasive surgical treatments for male LUTS due to benign prostatic enlargement and obstruction.
Why it matters: Offers practical consensus guidance for selecting among MIST options in BPH/LUTS management.
Female pelvic medicine and neurourology news
- Phase 3 trial registered testing berobenatide for stress incontinence in women with obesity Trial registered · ClinicalTrials.gov · 2026-11-12
A planned 900-participant, roughly 63-week trial will evaluate the safety and effectiveness of berobenatide in women with stress urinary incontinence who also have obesity or overweight. Registered on ClinicalTrials.gov and not yet recruiting; estimated start 2026-11-17; planned enrollment 900.
Why it matters: A positive trial could add a pharmacologic option for SUI in a population where weight is a known risk factor and surgical candidacy may be limited.
Reconstruction and trauma news
- Pump-preserving AUS revision feasible when pump is functioning normally Prospective · Urology · 2026-11-09
In a prospective single-center series of 60 artificial urinary sphincter revisions, surgeons preserved a normally functioning pump in all cases, with no pump-related complications and earlier device reactivation (2 weeks vs standard 6 weeks).
Why it matters: Suggests pump preservation may be a feasible option in selected AUS revisions to limit scrotal dissection and shorten reactivation time.
- Allium covered stents beat Memokath for radiation ureteral strictures but carry unique fistula risk Retrospective · World J Urol · 2026-11-09
Among 149 patients (205 ureteral units) treated for radiation-induced ureteral strictures, Allium stents showed higher 12- and 36-month primary success (75.9% vs 49.3% and 33.2% vs 23.2%) and cumulative success (96.3% vs 91.5% at 12 months, 64.0% vs 28.2% at 36 months) compared with Memokath stents, with median primary success duration of 30 vs 12 months (log-rank P < 0.001); ureteral fistulas occurred in 11 patients, exclusively in the Allium group.
Why it matters: For refractory radiation strictures, covered self-expandable stents may offer meaningfully longer patency than thermo-expandable stents, though the fistula signal tied to larger caliber and tandem stenting warrants careful sizing and patient selection.
- Meta-analysis: urethroplasty for post-BPH surgery bulbomembranous strictures shows 90% pooled patency Meta-analysis · BJU Int · 2026-11-01
A systematic review and meta-analysis of 417 patients from 9 observational studies found an overall pooled patency rate of 90% for urethroplasty after bulbomembranous strictures following BPH surgery, with patency around 87-94% depending on technique, though definitions of patency and continence varied widely.
Why it matters: Provides pooled benchmark patency rates for a challenging post-BPH stricture population, though heterogeneous outcome definitions and moderate-to-serious risk of bias limit certainty.
- Retrospective series reports outcomes after revision of difficult-to-catheterize continent channels Retrospective · Neurourol Urodyn · 2026-10-29
In a single-institution retrospective review of 45 adults undergoing 54 continent catheterizable channel revisions, 76% were free from reoperation at median 46-month follow-up, with success rates similar across suprafascial, subfascial, and replacement techniques.
Why it matters: Is hypothesis generating for channel revision technique selection given single-center retrospective design without randomized comparison.
Men's health news
- Eur Urol review updates classification systems and evidence gaps in male infertility Review · Eur Urol · 2026-11-13
A narrative review in European Urology summarizes new pathophysiological, endocrine (APHRODITE), and phenotypic classification systems for male factor infertility and highlights limited evidence for several add-on diagnostics and empirical therapies.
Why it matters: Offers urologists a current framework for classifying and evaluating male infertility beyond standard semen analysis.
- Company recalls supplement capsules with hidden sildenafil and acetaminophen FDA action · FDA · 2026-11-12
Game Changer Products LLC issued a voluntary nationwide recall of 10 Day Forecast Capsules after testing found undeclared sildenafil and acetaminophen, posing risks for patients on nitrates or with liver disease.
Why it matters: Patients using unregulated sexual-enhancement supplements may be unknowingly exposed to PDE5 inhibitors with drug interaction risks.
- Mail-in semen analysis kits show 93% completion within 16 weeks Prospective · J Urol · 2026-11-12
Among 35,444 patients using a national mail-in semen analysis platform, 93% completed testing within 16 weeks, with no meaningful differences by urbanization or neighborhood deprivation, though nearly a third tested before meeting guideline duration-of-infertility criteria.
Why it matters: Suggests mail-in semen analysis may reduce geographic and logistical barriers to male fertility evaluation.
Pediatric urology news
- Volumetric ratio may help select children for robotic nephrectomy in Wilms tumor Prospective · Eur Urol Oncol · 2026-11-08
In a prospective single-center series of 60 radical nephrectomies for presumptive Wilms tumor, about 40% (23/60) of children were selected for robot-assisted surgery using a new tumor-to-blood-volume ratio, with no significant difference in oncologic outcomes versus open surgery.
Why it matters: Suggests a volumetric selection criterion could help identify children suitable for robotic nephrectomy in Wilms tumor, pending external validation in larger cohorts.
- Review outlines when genetic testing is useful in CAKUT for urologists Review · Eur Urol Focus · 2026-11-08
A review discusses when genetic evaluation adds value in congenital anomalies of the kidney and urinary tract, emphasizing bilateral or severe anomalies, syndromic features, familial disease, and anatomy-function mismatch, while noting genetics should not drive surgical decisions alone.
- First multicentre study of Versius robot in pediatric urology reports interim safety data Prospective · J Pediatr Urol · 2026-11-06
In 60 procedures (mostly pyeloplasty) across three UK centres, 98.3% were completed robotically with one open conversion and no transfusions; median operative time was 195.5 minutes.
Why it matters: Early prospective data suggest the Versius platform may be feasible for pediatric minimally invasive urology, pending larger follow-up.
- Low-level pyuria tied to large jump in antibiotic prescribing for suspected pediatric UTI Retrospective · Pediatrics · 2026-11-06
Among 1150 pediatric ambulatory visits with urinalysis, 191 (16.6%) patients received antibiotics, and trace-to-low pyuria was associated with empiric antibiotic initiation (adjusted OR 6.62, 95% CI 3.72-11.79) versus no pyuria. This level of pyuria accounted for an adjusted attributable fraction of 17.0% (95% CI 10.3%-23.2%) for overtreatment in culture-negative children, compared with only 1.8% (95% CI 1.1%-2.4%) attributable fraction for treatment of culture-confirmed UTI.
Why it matters: Suggests that weighing degree of pyuria alongside age, symptoms, and risk factors rather than treating any pyuria as definitive could help reduce unnecessary antibiotic exposure in children evaluated for UTI.
- Thermocautery circumcision linked to far fewer early complications than bipolar sleeve or scalpel Retrospective · J Pediatr Urol · 2026-11-06
In a frequency-matched retrospective cohort of 31,100 boys, thermocautery guillotine circumcision had a complication rate of 0.6% versus 8.68% (bipolar sleeve) and 7.21% (scalpel guillotine), with zero bleeding events requiring suture ligation versus 15 and 25 respectively.
Why it matters: Raises the question of whether thermocautery technique reduces early circumcision complications, though retrospective design and single-center practice patterns limit causal inference.
- Nearly half of retractile testes ascend or need orchiopexy by age 7 in cohort study Prospective · J Urol · 2026-11-04
In a prospective single-institution cohort of 237 boys with retractile testicle(s) followed to median 7 years, cumulative incidence of testicular ascent was 47% and of orchiopexy was 57% by 84 months, with lower BMI and right-sided laterality associated with ascent.
Why it matters: Suggests boys with retractile testes warrant longer-term surveillance by a pediatric urologist rather than single-visit reassurance.
- New expert consensus aims to standardize surgery for pediatric kidney cancer Guideline · citybuzz - · 2026-11-03
A new expert consensus statement seeks to standardize surgical approach for childhood kidney cancer, according to the report.
Why it matters: A consensus statement may help reduce variability in surgical management of pediatric renal tumors.
- Multidisciplinary review addresses undescended testis management in medically complex children Review · J Urol · 2026-10-29
A narrative review by specialists across anesthesia, genetics, oncology, and urology examines how standard orchiopexy timing recommendations for undescended testis may need individualized reconsideration in children with syndromic or developmental conditions given elevated surgical risk.
Why it matters: Offers a framework for weighing surgical and anesthetic risk against fertility and oncologic benefit when managing undescended testis in medically complex children.
- AAP updates recommendations on management of UTI in children under age 5 Guideline · Renal & Urology News · 2026-10-16
The American Academy of Pediatrics has issued updated guidance on diagnosis and management of urinary tract infection in children under 5 years old.
Why it matters: Pediatric UTI guidance affects urology referral thresholds and imaging decisions for febrile young children.
Technology and AI news
- Dual-LLM consensus abstraction far more accurate than human abstraction in prostate registry Study · J Urol · 2026-11-12
In 3,210 pathology and 4,739 MRI reports from the Mayo Clinic Prostate Cancer Registry, consensus abstraction using two LLMs achieved median error rates of 0.09% (pathology) and 0.17% (MRI), compared with 2.81% and 1.01% for human abstractors; individual LLMs alone had error rates of 0.27-1.02%. Abstracting all 136,510 data elements took an estimated 32 hours with the LLM pipeline versus 952 hours for human abstraction.
Why it matters: A dual-LLM consensus architecture may substantially cut abstraction time and errors for large clinical registries, supporting consideration for integration into prospectively maintained databases.
- Gemini and ChatGPT outperform Claude in matching expert consensus on prostate cancer guideline questions Study · UroToday · 2026-11-09
In a two-round Delphi study, 11 experts evaluated 25 guideline-based prostate cancer questions answered by three LLMs: consensus agreement was reached for 23/25 (92%) Gemini responses, 20/25 (80%) ChatGPT responses, and 14/25 (56%) Claude responses (p=0.0033), with explicit disagreement noted for 3 Claude answers after round two.
Why it matters: Suggests LLMs like Gemini and ChatGPT may assist in interpreting routine guideline content but require expert oversight, with notably lower reliability from Claude, especially in complex scenarios involving advanced imaging or genetic testing.
More urology news
- Registered trial: phase 3 trial to test oral fosfomycin versus standard antibiotics for febrile UTI in men Trial registered · ClinicalTrials.gov · 2026-11-12
A planned 312-patient non-inferiority trial will compare oral fosfomycin-trometamol to fluoroquinolones or cotrimoxazole as step-down therapy for febrile UTI/prostatitis in men caused by E. coli, a use not previously studied prospectively. Registered on ClinicalTrials.gov and not yet recruiting; estimated start 2026-12-01; planned enrollment 312.
Why it matters: If non-inferior, fosfomycin could offer a lower-side-effect oral option for step-down therapy of febrile UTI in men.
Loading today's edition…